NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU - NEUREN PHARMACEUTICALS LIMITED

Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: N/A
Index: ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$19.45

16 Apr
2024

-0.950

OPEN

$20.19

-4.66%

HIGH

$20.28

334,156

LOW

$19.38

TARGET
$27.00 38.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 85.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 22.7 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx123.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx231.9 M
Book Value Per Share xxxxxxxxxxxxxxx161.2
Net Operating Cash Flow xxxxxxxxxxxxxxx184.9 M
Net Profit Margin xxxxxxxxxxxxxxx67.73 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx127.30 %
Return on Invested Capital xxxxxxxxxxxxxxx127.30 %
Return on Assets xxxxxxxxxxxxxxx107.87 %
Return on Equity xxxxxxxxxxxxxxx127.30 %
Return on Total Capital xxxxxxxxxxxxxxx161.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx184.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx-
Long Term Debt xxxxxxxxxxxxxxx-
Total Debt xxxxxxxxxxxxxxx-
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx229 M
Price To Book Value xxxxxxxxxxxxxxx15.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.02 %
Cost of Goods Sold xxxxxxxxxxxxxxx-
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx33 M
Research & Development xxxxxxxxxxxxxxx27 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/03/2024

1

Buy

$27.00

38.82%

Fourth quarter Daybue sales were up 30% quarter on quarter and near the top end of Acadia’s guidance range, Bell Potter reports. Holiday seasonality impacts are expected to result in a temporary decline this quarter.

2024 implies 6%-21% growth on current fourth quarter annualised sales. It was thus a "stellar" 2023 for Neuren Pharmaceuticals, and licencing royalties from Arcadia will keep flowing in 2024, the broker notes.

It was a "clearly transformational year" from a clinical, regulatory, and financial perspective. Buy and $27 target retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of 85.80 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 73.30 cents.

NEU STOCK CHART